- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02755857
Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis
A Single-arm, Multiple-Dose, Steady-State, Bioavailability Study With Twice Daily Dosing of Lozanoc™ (65 mg Itraconazole Capsules, Mayne) Taken Regardless of Food
Study Overview
Detailed Description
After confirmation of eligibility, participants will take their last dose of current itraconazole therapy (Lozanoc 50mg capsules or Sporanox 100mg capsules) on the morning of Day 1, and commence therapy with Lozanoc 65 mg capsules for 21 days from the evening of Day 1.
The number of Lozanoc 65mg capsules to be taken by the participant will be 2 capsules (130mg) morning and evening OR the same number of Lozanoc 50mg capsules that the participant received in study MPG010, if applicable. That is, if the participant received 3 x 50mg Lozanoc capsules morning and evening on study MPG010 he/she will receive 3 x 65 mg Lozanoc 65 mg capsules, morning and evening in study MPG011
The dose of study drug (Lozanoc 65mg) may be dose-reduced or ceased for toxicity at the discretion of the investigator.
Participants will undergo the following assessments during the course of the study:
- Concurrent medication(s)
- Clinical adverse events
- Measurement of vital signs (weight, blood pressure, temperature)
- Targeted physical examination
- Documentation of any evidence of systemic fungal infection
- Medication and meal diaries
- 12-lead electrocardiogram (ECG)
Laboratory safety assessments
- Renal function and electrolytes (urea, creatinine, estimated glomerular filtration rate [eGFR], sodium, potassium, chlorine, bicarbonate)
- Liver function tests (bilirubin, albumin, total protein, alanine aminotransferase [ALT], aspartate aminotransferase [AST])
Pharmacokinetic testing
- pre-morning dose (0 h sample) at Baseline (Day 1), and at Days 8, 15, and 22
- at 2, 3.5 and 6 hours post the morning dose at Baseline (Day 1) and Day 22
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- St Vincent's hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of written, informed consent
- Age of at least 18 years
- No clinical evidence of active systemic fungal infection
Physician-recommended continuation of oral itraconazole as primary prophylaxis in patients at risk of systemic fungal infections or otherwise requiring a long-term itraconazole maintenance regimen, including patients:
- who have had or are about to have a heart, lung or bone marrow transplant
- on combination chemotherapy for cancer
- with an aspergilloma, chronic pulmonary aspergillus bronchitis, or allergic bronchopulmonary aspergillosis
- At least 21 days of prior dosing with oral itraconazole, either Lozanoc 50mg capsules twice daily or Sporanox 100mg capsules twice daily.
- Body mass index between 15.0 and 35.0 kg/m2
Exclusion Criteria:
- Pregnant, planning pregnancy or breastfeeding
- Plasma itraconazole concentration greater than 1500ng/mL (in patients on Lozanoc 50mg capsules)
- Congestive cardiac failure or other causes of ventricular dysfunction that may outweigh the benefit of itraconazole
- Hypersensitivity to Lozanoc or to any of its excipients
Coadministration of the following drugs:
- CYP3A4 metabolised substrates that can prolong the QT-interval: sertindole, terfenadine
- CYP3A4 metabolised 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors: simvastatin, lovastatin
- Potent CYP3A4 inhibitor: dronedarone
- Triazolam, alprazolam and oral midazolam
- Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and ergotamine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lozanoc
65 mg, capsules, at least 2 capsules twice a day
|
65 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Steady-state plasma itraconazole concentrations
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Deborah Marriott, MBBS BSc(MED) FRACP FRCPA, St Vincent's hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Agranulocytosis
- Leukopenia
- Leukocyte Disorders
- Neutropenia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Itraconazole
Other Study ID Numbers
- MPG011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neutropenia
-
Hospira, now a wholly owned subsidiary of PfizerCompletedSolid Tumors | Malignant Hemopathy | Chemotherapy-induced Febrile Neutropenia (FN)France
-
University of Mississippi Medical CenterUnknownPediatric Cancer | Chemotherapy-Induced Febrile Neutropenia | Chemotherapy-induced Neutropenia | Granulocyte Colony-Stimulating FactorUnited States
-
TTY BiopharmCompletedNeutropenia, FebrileTaiwan
-
Institut RafaelActive, not recruitingPatient Satisfaction | Patient Preference | Febrile Neutropenia, Drug-InducedFrance
-
CinnagenCompletedChemotherapy-induced Neutropenia
-
University Hospital, BrestCompletedNeutropenia, FebrileFrance
-
University Hospital Inselspital, BerneCompletedFebrile Neutropenia | Pediatric Cancer | Oncology | Chemotherapy-induced NeutropeniaSwitzerland
-
University Hospital Inselspital, BerneCompletedFebrile Neutropenia | Pediatric Cancer | Oncology | Chemotherapy-induced NeutropeniaSwitzerland
-
PfizerCompletedNon-Interventional StudyGermany
-
BeyondSpring Pharmaceuticals Inc.CompletedChemotherapy-induced NeutropeniaChina, Russian Federation, United States, Ukraine
Clinical Trials on Lozanoc
-
Boryung Pharmaceutical Co., LtdCompletedCandidiasis | Dermatomycoses | Histoplasmosis | Superficial MycosesKorea, Republic of
-
Mayne Pharma International Pty LtdCompleted
-
University of California, San FranciscoCompletedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7United States
-
Jean Yuh TangNational Cancer Institute (NCI)CompletedSkin Basal Cell CarcinomaUnited States
-
Jean Yuh TangWithdrawnSkin Basal Cell Carcinoma